Adding programmed death 1/programmed death ligand 1 inhibitors to first-line standard-of-care therapy for metastatic colorectal cancer: A meta-analysis
Meta-analysis shows PD-1/L1 inhibitors fail to improve overall survival in metastatic colorectal cancer, suggesting limited benefits.
Key Points
Combination of PD-1/L1 inhibitors showed a significant PFS advantage over SOC monotherapy, with a hazard ratio of 0.8 in intention-to-treat populations.
The MSS/pMMR subgroup displayed no PFS benefit and overall survival improvements were not observed, highlighting ongoing uncertainty in treatment efficacy.
Systematic review included six randomized controlled trials with 675 metastatic colorectal cancer patients undergoing first-line treatment.
Findings underscore the need for rigorously designed phase III trials to confirm the therapeutic impact and safety of PD-1/L1 inhibitors.